

Seminars in Thrombosis & Hemostasis

Volume 34 Supplement 1 October 2008

Editor in Chief

Eberhard F. Mammen, MD., USA


Regional Editors

Emmanuel J. Favaloro, Ph.D., Australia

Craig M. Kessler, M.D., USA

Marcel Levi, M.D., Ph.D., The Netherlands

A SATELLITE SYMPOSIUM OF
THE XXIst CONGRESS OF THE INTERNATIONAL
SOCIETY ON THROMBOSIS AND HAEMOSTASIS
AND THE 53rd ANNUAL MEETING



LANDMARKS IN
ANTI-THROMBIN
DRUG DEVELOPMENT
THE ARGATROBAN STORY

Wednesday, July 11, 2007
5:30 pm – 10:00 pm

*This symposium is being presented in memory of
Professor Dr. Med. Dr. H.C. Hans Klaus Areschoug*

Palexpo – Jura Room
Chemin Edouard Sarasin
1218 Le Grand-Saconnex
Geneva, Switzerland

LOYOLA
MEDICINE

supported by
Lilly, Novartis, Bristol-Myers Squibb, Amgen,
Genzyme, and others. The symposium is part
of the 2007 International Society on Thrombosis and
Haemostasis (ISTH) Congress, which will be held
in Geneva, Switzerland, from July 14-18, 2007.

Landmarks in Anti-Thrombin Drug Development: The Argatroban Story

Guest Editors

Jeanine M. Walenga, Ph.D.

Henri Bounameaux, M.D.

Yasuo Ikeda, M.D.

Seminars in Thrombosis and Hemostasis

Editor in Chief

Eberhard F. Mammen, M.D.
Wayne State University
School of Medicine
Mott Center
275 East Hancock
Detroit, MI 48201

Regional Editors

Emmanuel J. Favaloro, Ph.D.
Westmead Hospital
Institute of Clinical Pathology and
Medical Research
Westmead NSW 2145
Australia

Craig M. Kessler, M.D.
Lombardi Cancer Center
Georgetown University
3800 Reservoir Road NW
Washington, DC, 20007

Marcel Levi, M.D., Ph.D.
Department of Medicine
University of Amsterdam
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands

Associate Editors

Benjamin Brenner, M.D.
Department of Hematology
Rambam Medical Center
Haifa, 31096
Israel

Jawed Fareed, Ph.D.
Departments of Pathology and
Pharmacology
Loyola University Medical Center
21603 First Avenue
Maywood, IL 60153

Job Harenberg, M.D.
IV Department of Medicine

University Hospital Mannheim
Theodor-Kutzer-Ufer
D-68167 Mannheim
Germany

W. Keith Hoots, M.D.
Gulf State Hemophilia and
Thrombophilia Center
University of Texas-Houston
6655 Travis HMC
Houston, TX 77030

Steve Kitchen, Ph.D.
Dept of Coagulation
Royal Hallamshire Hospital
Glossop Road
Sheffield S10 2 JF
United Kingdom

Giuseppe Lippi, M.D.
Sezione di Chimica Clinica
Dipartimento di Scienze Biomediche e
Morfologiche Università di Verona
P. le Scuro 10
37134 - Verona
Italy

Arnaud Perrier, M.D.
Department of Medicine
Geneva University Hospital
Rue Micheli-du-Crest 24
CH-1211 Geneva 14
Switzerland

Nobuo Sakuragawa, M.D., Ph.D.
Niigata Research Institute and Toyoura
Hospital
Sibata-City, 959-2311
Japan

Sam Schulman, M.D.
Department of Medicine
Thrombosis Center

McMaster Clinic
HHS-General Hospital
237 Barton Street East
Hamilton, ON L8L 2X2
Canada

Mark P. Smith, M.B.Ch.B.
Consultant Hematologist
Canterbury District Health Board
Box 151
Christchurch
New Zealand

Alok Srivastava, M.D.
Department of Hematology
Christian Medical College
Vellore, 632004
India

Leo R. Zacharski, M.D.
Department of Veteran Affairs
Medical and Regional Office Center
215 North Main Street
White River Junction, VT 05001

Guest Editors

Jeanine M. Walenga, Ph.D.
Professor
Thoracic & Cardiovascular Surgery
and Pathology
Loyola University Medical Center
2160 S. First Avenue
Maywood, IL 60153

Henri Bounameaux, M.D.
Professor
Division of Angiology and Hemostasis
University Hospitals of Geneva (HUG)
and Faculty of Medicine
Hôpital Cantonal
CH-1211 Geneva 14
Switzerland

Yasuo Ikeda, M.D.
Professor
Department of Internal Medicine,
Division of Hematology/Oncology
Keio University, School of Medicine
35 Shinanomachi
Shinjuku-ku, Tokyo 160-8582
Japan

Copyright © 2008 by Thieme Medical Publishers, Inc. *Seminars in Thrombosis and Hemostasis* is published eight times a year in February, March, April, June, July, September, October, and November by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001.

Subscription price per volume in the United States is \$695.00 for libraries and institutions, \$264.00 for individuals, \$108.00 for residents; outside the United States, \$719.00 for libraries and institutions, \$305.00 for individuals. Single issues are available for \$88.00; outside the United States, add \$5.00 per issue. Periodicals postage is paid at New York, NY and additional mailing offices. POSTMASTER: send changes of address to the *Seminars in Thrombosis and Hemostasis*, Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001. Copies not received will be replaced upon written notification to the Publisher. Notification must be received within three months of issue date for U.S. subscribers, and within four months of issue date outside the United States. Subscribers outside The Americas: price per volume is €745.00 for libraries and institutions, €292.00 for individuals, plus €68.00 for postage in

Germany. Contact: Georg Thieme Verlag, Postfach 30 11 20, D-70451 Stuttgart, Germany.

Editorial comments should be sent to journals@thieme.com. Articles may be submitted to this journal on an open-access basis. For further information, please send an e-mail to openaccess@thieme.com. The content of this journal is available online at www.thieme-connect.com/ejournals. Visit our Web site at www.thieme.com and the direct link to this journal at www.thieme.com/sth.

Seminars in Thrombosis and Hemostasis is listed in *Biological Abstracts*, *BIOSIS*, *Chemical Abstracts*, *Current Contents/Clinical Medicine*, *Current Contents/Life Sciences*, *EMBASE*, *Excerpta Medica*, *Index International de Cardiologia*, *Index Medicus*, *MEDLINE*, *Reference Update*, *Research Alert*, *Science Citation Index*, and *Scisearch*. Thieme Medical Publishers is a member of the CrossRef initiative.

Advertisers in North and South America contact: Cunningham Associates, 180 Old Tappan Road, Old Tappan, NJ 07675. Advertisers outside The Americas contact: Pharmedia, Anzeigen und Verlagsservice GmbH, Postfach 30 08 80, D-70448 Stuttgart, Germany.

ISSN 0094-6176.

Seminars in Thrombosis and Hemostasis

VOLUME 34, SUPPLEMENT 1 2008

Landmarks in Anti-Thrombin Drug Development: The Argatroban Story

Jeanine M. Walenga, Ph.D., Henri Bounameaux, M.D., and Yasuo Ikeda, M.D.

CONTENTS

- 1 Preface
Jeanine M. Walenga, Ph.D., Henri Bounameaux, M.D., and Yasuo Ikeda, M.D.
- 3 Foreword
Fritz Markwardt, M.D., Ph.D.
- 5 A Tribute to Professor Hans Klaus Breddin
Jawed Fareed, Ph.D., and Jeanine M. Walenga, Ph.D.
- 7 Okamoto's Strategy to Develop Argatroban: An Innovative Concept for the Future
Yasuo Ikeda, M.D., Keiko Wanaka, Ph.D., and Utako Okamoto, M.D.
- 12 Overview of Direct Thrombin Inhibitors in Clinical Practice
Henri Bounameaux, M.D.
- 18 Mechanisms Involved in Heparin-Induced Thrombocytopenia and Associated Thrombosis
Anne Marie Vissac, M.T., and Jean Amiral, Ph.D.
- 27 Overview of Heparin-Induced Thrombocytopenia. Diagnosis and Treatment in Europe with an Emphasis on France
Yves Gruel, M.D., and Claire Pouplard, Ph.D.
- 37 Heparin-Induced Thrombocytopenia Clinical Studies and the Efficacy of Argatroban in Japan
Shigeki Miyata, M.D., Ph.D., Haruko Yamamoto, M.D., Ph.D., Masataka Kamei, M.D., Ph.D., Takeshi Nakatani, M.D., Ph.D., Junjiro Kobayashi, M.D., Ph.D., Tetsu Tsuji, M.T., Kazuo Minematsu, M.D., Ph.D., and Hitonobu Tomoike, M.D., Ph.D.



THIEME

New York • Stuttgart

Copyright © 2008 by Thieme Medical Publishers, Inc.

333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

- 48** Clinical Experience of Argatroban in Germany
Carl-Erik Dempfle, M.D.
- 52** Argatroban Anticoagulation in Patients following Cardiovascular Surgery and in ICU Patients with and without Renal-Replacement Therapy
Andreas Koster, M.D., Ph.D., and Karl-Georg Fischer, M.D., Ph.D.
- 56** Hemodialysis and Argatroban
Takefumi Matsuo, M.D., and Keiko Wanaka, Ph.D.
- 62** Argatroban in Percutaneous Coronary Interventions
Omer Iqbal, M.D., Cafer Adiguzel, M.D., Bruce E. Lewis, M.D., Josephine Cunanan, M.D., and Jawed Fareed, Ph.D.
- 75** The Direct Thrombin Inhibitor Argatroban: A Review of Its Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships
Sebastian Harder, M.D., Andreas Koster, M.D., and Ute Klinkhardt, M.D.
- 81** Drug Monitoring of Argatroban Using the Ecarin Chromogenic Assay
Götz Nowak, M.D., Ute Lange, Ph.D., and Elke Bucha, M.D.
- 87** Effect of Argatroban versus Recombinant Hirudin on Tissue-Factor-Mediated Thrombin Generation: An in Vitro Study
Meyer Michel Samama, M.D., Pharm.D., Léna Le Flem, Ph.D., Céline Guinet, and François Depasse, Pharm.D.
- 91** In Vitro Effects of Argatroban, Lepirudin, Bivalirudin, and Danaparoid on Fibrin Gel Permeability
Shu He, M.D., Ph.D., Håkan Wallen, Ph.D., Hans Johnsson, Ph.D., and Margareta Blombäck, Ph.D.
- 97** The Anti-Inflammatory Effects of Argatroban Can Be Differentiated from other Direct Thrombin Inhibitors: Experimental and Clinical Observations
Debra A. Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Jeanine M. Walenga, Ph.D., Rodger L. Bick, M.D., Ph.D., F.A.C.P., and Jawed Fareed, Ph.D.
- 103** Influence of Renal and Hepatic Failure on the Pharmacokinetics of Argatroban: An Experimental Study in Rats
Mercedes Lopez, Ph.D., and Götz Nowak, M.D.
- 108** Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays
Cafer Adiguzel, M.D., Omer Iqbal, M.D., Josephine Cunanan, M.D., Walter Jeske, Ph.D., Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, Ph.D., and Jawed Fareed, Ph.D.
- 119** Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin
Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., Walter P. Jeske, Ph.D., Debra Hoppensteadt, Ph.D., Margaret Prechel, Ph.D., Omer Iqbal, M.D., Cafer Adiguzel, M.D., Melanie Clark, B.S., Evangelos Litinas, M.D., Josephine Cunanan, M.D., Robert Linhardt, Ph.D., and Job Harenberg, M.D.

128 Dr. Eberhard F. Mammen Remembered

*Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., Debra A. Hoppensteadt, Ph.D.,
Rodger L. Bick, M.D., Ph.D., F.A.C.P., and Harry L. Messmore, M.D., Ph.D.*

Cover figure: Cover of the booklet distributed at the 2007 ISTH symposium on argatroban with the chemical structure of argatroban in the background.

Some of the product names, patents, and registered designs referred to in this publication are in fact registered trade marks or proprietary names even though specific reference to this fact is not always made in the text. Therefore, the appearance of a name without designation as proprietary is not to be construed as a representation by the Publisher that it is in the public domain.

All rights, including the rights of publication, distribution, and sales, as well as the right to translation, are reserved. No part of this work covered by the copyrights hereon may be reproduced or copied in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, or information and retrieval systems—without written permission of the Publisher.

Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy may be required. The authors and editors of the material herein have consulted sources believed to be reliable in their efforts to provide information that is complete and in accord with the standards accepted at the time of publication. However, in view of the possibility of human error by the authors, editors, or publisher of the

work herein, or changes in medical knowledge, neither the authors, editors, or publisher, nor any other party who has been involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from use of such information. Because of rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made. Readers are encouraged to confirm the information contained herein with other sources. For example, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this publication is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this journal does not constitute a guarantee or endorsement of the quality or value of such product or of claims made by its manufacturer.